Discover
PHVS
Pharvaris N.V.
31.10
2 x 22.92
2 x 40.00
bid
ask
-
0.02
0.06%
2 @ 04:00 PM
31.10 +0.00 (0.00%)
| Ytd | 12.07% | |
| 1y | 36.16% |
31.09
day range
31.91
20.96
52 week range
38.86
| Open | 31.14 | Prev Close | 31.12 | Low | 31.09 | High | 31.91 | Mkt Cap | 2.18B |
| Vol | 754.99K | Avg Vol | 711.75K | EPS | -3.06 | P/E | N/A | Forward P/E | -10.24 |
| Beta | -2.46 | Short Ratio | 1.70 | Inst. Own | 93.31% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 34.83 | 200-d Avg | 30.58 | 1yr Est | 57.23 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-11-11 | 2026-09 | -0.82 | N/A | N/A | N/A |
| 2026-08-12 | 2026-06 | -0.75 | -0.81 | -0.06 | -8.48% |
| 2026-05-12 | 2026-03 | -0.82 | -0.7 | 0.12 | 14.83% |
| 2026-04-02 | 2025-12 | -0.71 | -0.85 | -0.13 | -18.34% |
| 2025-11-12 | 2025-09 | -0.78 | -0.7 | 0.08 | 10.26% |
| 2025-08-12 | 2025-06 | -0.87 | -0.94 | -0.07 | -8.05% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-09-10 | Guggenheim | Upgrade | Buy | Buy |
| 2026-09-09 | Morgan Stanley | Upgrade | Overweight | Overweight |
| 2026-09-09 | Leerink Partners | Upgrade | Outperform | Outperform |
| 2026-09-09 | Wells Fargo | Upgrade | Overweight | Overweight |
| 2026-09-09 | RBC Capital | Upgrade | Outperform | Outperform |
| 2026-09-09 | Citizens | Upgrade | Market Outperform | Market Outperform |
Profile
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-09-14 | ABELE STEFAN | Chief Operating Officer | 39.07K | Sale |
| 2026-09-16 | BJORK ELISABETH | Director | 15.17K | Sale |
| 2026-09-16 | GLASSMAN ROBERT R. | Director | 10.50K | Sale |
| 2026-09-16 | LESAGE ANNE SIMONNE J PH.D. | Officer | 0.00 | Sale |
| 2026-09-21 | LU PENG | President | 110.26K | Conversion of Exercise of derivative security |
| 2026-09-16 | MODIG BERNDT B.A.E | Chief Executive Officer | 0.00 | Conversion of Exercise of derivative security |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | FMR, LLC | 6.57M | 204.18M | 10.04% |
| 2026-06-29 | General Atlantic, L.P. | 6.55M | 203.73M | 10.02% |
| 2026-06-29 | Foresite Capital Management IV, LLC | 4.78M | 148.61M | 7.31% |
| 2026-06-29 | venBio Partners LLC | 4.64M | 144.41M | 7.10% |
| 2026-06-29 | Viking Global Investors, L.P. | 3.65M | 113.62M | 5.59% |
| 2026-06-29 | Eqt Fund Management S.a R.l. | 3.42M | 106.51M | 5.24% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-08-30 | Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 1.37M | 42.71M | 2.10% |
| 2026-07-30 | VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 1.17M | 36.24M | 1.78% |
| 2026-08-30 | Fidelity Select Portfolios-Select Health Care Portfolio | 800.00K | 24.88M | 1.22% |
| 2026-07-30 | Fidelity Securities Fund-Fidelity Small Cap Growth Fund | 644.59K | 20.05M | 0.99% |
| 2026-08-30 | Fidelity Advisor Series VII-Fidelity Advisor Health Care Fund | 400.00K | 12.44M | 0.61% |
| 2026-08-30 | Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund | 399.48K | 12.42M | 0.61% |